• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Public Health . The Rapid Antigen Detection Test for SARS-CoV-2 Underestimates the Identification of COVID-19 Positive Cases and Compromises t

tetano

Editor, Senior Moderator
Front Public Health


. 2022 Jan 3;9:780801.
doi: 10.3389/fpubh.2021.780801. eCollection 2021.
The Rapid Antigen Detection Test for SARS-CoV-2 Underestimates the Identification of COVID-19 Positive Cases and Compromises the Diagnosis of the SARS-CoV-2 (K417N/T, E484K, and N501Y) Variants


Carlos Barrera-Avalos[SUP] 1 [/SUP], Roberto Luraschi[SUP] 1 [/SUP], Eva Vallejos-Vidal[SUP] 1 2 [/SUP], Andrea Mella-Torres[SUP] 1 [/SUP], Felipe Hernández[SUP] 1 [/SUP], Maximiliano Figueroa[SUP] 1 [/SUP], Claudia Rioseco[SUP] 1 [/SUP], Daniel Valdés[SUP] 1 3 [/SUP], Mónica Imarai[SUP] 1 3 [/SUP], Claudio Acuña-Castillo[SUP] 1 3 [/SUP], Felipe E Reyes-López[SUP] 1 4 5 [/SUP], Ana María Sandino[SUP] 1 3 [/SUP]



Affiliations

Abstract

Timely detection of severe acute respiratory syndrome due to coronavirus 2 (SARS-CoV-2) by reverse transcription quantitative polymerase chain reaction (RT-qPCR) has been the gold- strategy for identifying positive cases during the current pandemic. However, faster and less expensive methodologies are also applied for the massive diagnosis of COVID-19. In this way, the rapid antigen test (RAT) is widely used. However, it is necessary to evaluate its detection efficiency considering the current pandemic context with the circulation of new viral variants. In this study, we evaluated the sensitivity and specificity of RAT (SD BIOSENSOR, South Korea), widely used for testing and SARS-CoV-2 diagnosis in Santiago of Chile. The RAT showed a 90% (amplification range of 20 ≤ Cq <25) and 10% (amplification range of 25 ≤ Cq <30) of positive SARS-CoV-2 cases identified previously by RT-qPCR. Importantly, a 0% detection was obtained for samples within a Cq value>30. In SARS-CoV-2 variant detection, RAT had a 42.8% detection sensitivity in samples with RT-qPCR amplification range 20 ≤ Cq <25 containing the single nucleotide polymorphisms (SNP) K417N/T, N501Y and E484K, associated with beta or gamma SARS-CoV-2 variants. This study alerts for the special attention that must be paid for the use of RAT at a massive diagnosis level, especially in the current scenario of appearance of several new SARS-CoV-2 variants which could generate false negatives and the compromise of possible viral outbreaks.

Keywords: COVID-19 diagnosis; COVID-19 false negative rapid test for COVID-19 diagnosis; SARS-CoV-2 detection; pandemic control strategies; rapid antigen test.
 
Back
Top Bottom